Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research and Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Infect Immun. 2013 Dec;81(12):4626-34. doi: 10.1128/IAI.00915-13. Epub 2013 Oct 7.
Infections with the Gram-negative bacterium Burkholderia pseudomallei (melioidosis) are associated with high mortality, and there is currently no approved vaccine to prevent the development of melioidosis in humans. Infected patients also do not develop protective immunity to reinfection, and some individuals will develop chronic, subclinical infections with B. pseudomallei. At present, our understanding of what constitutes effective protective immunity against B. pseudomallei infection remains incomplete. Therefore, we conducted a study to elucidate immune correlates of vaccine-induced protective immunity against acute B. pseudomallei infection. BALB/c and C57BL/6 mice were immunized subcutaneously with a highly attenuated, Select Agent-excluded purM deletion mutant of B. pseudomallei (strain Bp82) and then subjected to intranasal challenge with virulent B. pseudomallei strain 1026b. Immunization with Bp82 generated significant protection from challenge with B. pseudomallei, and protection was associated with a significant reduction in bacterial burden in lungs, liver, and spleen of immunized mice. Humoral immunity was critically important for vaccine-induced protection, as mice lacking B cells were not protected by immunization and serum from Bp82-vaccinated mice could transfer partial protection to nonvaccinated animals. In contrast, vaccine-induced protective immunity was found to be independent of both CD4 and CD8 T cells. Tracking studies demonstrated uptake of the Bp82 vaccine strain predominately by neutrophils in vaccine-draining lymph nodes and by smaller numbers of dendritic cells (DC) and monocytes. We concluded that protection following cutaneous immunization with a live attenuated Burkholderia vaccine strain was dependent primarily on generation of effective humoral immune responses.
感染革兰氏阴性细菌伯克霍尔德氏菌(类鼻疽)与高死亡率相关,目前尚无批准的疫苗可预防人类类鼻疽的发生。感染的患者也不会对再感染产生保护性免疫,一些人会发展为慢性、亚临床的伯克霍尔德氏菌感染。目前,我们对构成针对伯克霍尔德氏菌感染的有效保护性免疫的因素了解仍不完整。因此,我们进行了一项研究,以阐明针对急性伯克霍尔德氏菌感染的疫苗诱导保护性免疫的免疫相关性。BALB/c 和 C57BL/6 小鼠经皮下接种高度减毒、排除选择剂的伯克霍尔德氏菌 purM 缺失突变株(菌株 Bp82),然后经鼻腔接受毒力菌株 1026b 的攻击。Bp82 免疫可显著预防 B. pseudomallei 挑战,保护与免疫小鼠肺部、肝脏和脾脏中的细菌负荷显著降低相关。体液免疫对疫苗诱导的保护至关重要,因为缺乏 B 细胞的小鼠不能通过免疫得到保护,并且来自 Bp82 疫苗接种小鼠的血清可以将部分保护作用转移到未接种疫苗的动物。相比之下,疫苗诱导的保护性免疫与 CD4 和 CD8 T 细胞均无关。跟踪研究表明,Bp82 疫苗株主要被疫苗引流淋巴结中的中性粒细胞和数量较少的树突状细胞(DC)和单核细胞摄取。我们得出结论,经皮接种活减毒伯克霍尔德氏菌疫苗后产生的保护作用主要依赖于产生有效的体液免疫反应。